Extra proxy material
Open the filing on sec.gov
Processa Pharmaceuticals, Inc. (PCSA)
Nasdaq: PCSA · Pharmaceutical Preparations · Vero Beach, FL · filing with the SEC since 2011
The companyfiscal 2022, as filed
Revenue$0.00
Net income-$27.4M-140.0%
Earnings per share$-851.25-127.0%
Operating cash flow-$9.6M-10.2%
Cash$6.5M-60.6%
Debtn/a
Shareholders’ equity$7.5M-70.7%
Shares, diluted32,219+5.2%
Return on equity-243.2%
The recordfrom its filings
Filings in 202689
Newest filingNov 5 · DEFA14A
Annual reportMar 18, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$200,000
Patents granted7
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$13.4MCash from operations -$12.0Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Extra proxy material
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Proxy statement
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Preliminary proxy statement
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.